Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6

Chemistry Central Journal

Georgia Sotiropoulou²  Georgios Pampalakis²  Evangelia Prosnikli²  Gregory P Evangelatos¹  Evangelia Livaniou¹ 

[1] Institute of Radioisotopes & Radiodiagnostic Products, Immunopeptide Chemistry Laboratory, National Centre for Scientific Research (NCSR) “Demokritos”, 153 10, Aghia Paraskevi-Attiki, Greece

[2] Department of Pharmacy, University of Patras, 265 00, Rion-Patras, Greece

关键词: Immunoassays;    IgY;    Kallikrein-related peptidase 6(KLK6);   

Others  :  788007
DOI  :  10.1186/1752-153X-6-148

 received in 2012-10-11, accepted in 2012-11-19,  发布年份 2012

【 摘 要 】

Background

Human kallikrein-related peptidase 6 (KLK6) has been implicated in various types of cancer and in neurodegenerative and demyelinating diseases including multiple sclerosis. Further, anti-KLK6 antibodies attenuated disease manifestations in the mouse model of multiple sclerosis. Availability of specific antibodies against KLK6 is fundamental to the development of improved diagnostic and/or immunotherapeutic applications. Here, we exploited the enhanced immunogenicity of mammalian proteins in avian species to generate a polyclonal antibody against KLK6.

Results

Chicken were immunized with recombinant KLK6 and antibodies Y (IgYs) were purified from egg yolk with a simple procedure and evaluated for KLK6 detection by ELISA and Western blot using recombinant proteins and human cell lysates and supernatants. The anti-KLK6 Y polyclonal exhibited high affinity for KLK6 with a detection limit of 30 fmol. On the other hand, the widely used rabbit polyclonal antibody that was raised against the same recombinant KLK6 had a detection limit of 300 fmol. Moreover, the IgYs did not display any crossreactivity with recombinant KLKs or endogenous KLKs and other cellular proteins.

Conclusions

Based on its high specificity and sensitivity the developed anti-KLK6 IgY is expected to aid the development of improved diagnostic tools for the detection of KLK6 in biological and clinical samples.

【 授权许可】

   
2012 Sotiropoulou et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Zhang WW: The use of gene-specific IgY antibodies for drug target discovery. Drug Discov Today 2003, 8:364-371.
• [2]Dias da Silva W, Tambourgi DV: IgY: a promising antibody for use in immunodiagnostic and immunotherapy. Vet Immunol Immunopathol 2010, 135:173-180.
• [3]Leslie GA, Clem LW: Phylogeny of immunoglobulin structure and function. 3. Immunoglobulins of the chicken. J Exp Med 1969, 130:1337-1352.
• [4]Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R: A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996, 2:624-636.
• [5]Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, Diamandis EP: The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001, 49:1431-1441.
• [6]Pampalakis G, Kurlender L, Diamandis EP, Sotiropoulou G: Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochem Biophys Res Commun 2004, 320:54-61.
• [7]Yousef GM, Borgoño CA, White NM, Robb JD, Michael IP, Oikonomopoulou K, Khan S, Diamandis EP: In silico analysis of the human kallikrein gene 6. Tumour Biol 2004, 25:282-289.
• [8]Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov NI, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis EP, Langer R, Sweep FC, Schmitt M, Magdolen V: Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem 2012, 393:391-401.
• [9]Shan SJ, Scorilas A, Katsaros D, Diamandis EP: Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br J Cancer 2007, 96:362-372.
• [10]Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99:267-277.
• [11]Kim JT, Song EY, Chung KS, Kang MA, Kim JW, Kima SJ, Yeom YI, Kim JH, Kim KH, Lee HG: Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer 2011, 117:2608-2619.
• [12]Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, Mori M: Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005, 11:6800-6806.
• [13]Gabril M, White NM, Moussa M, Chow TF, Metias SM, Fatoohi E, Yousef GM: Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications. Biol Chem 2010, 391:403-409.
• [14]Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res 2005, 11:3320-3325.
• [15]Sotiropoulou G, Pampalakis G, Diamandis EP: Functional roles of human kallikrein-related peptidass. J Biol Chem 2009, 284:32989-32994.
• [16]Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP: Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 2004, 25:193-199.
• [17]Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafiropoulos N, Simillides G, Yiotakis A, Diamandis EP: Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res 2003, 13:381-391.
• [18]Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G: A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res 2009, 69:3779-3787.
• [19]Nathalie HV, Chris P, Serge G, Catherine C, Benjamine B, Claire B, Christelle P, Briollais L, Pascale R, Marie-Lise J, Yves C: High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J Cell Mol Med 2009, 13:4014-4022.
• [20]Menendez-Gonzalez M, Castro-Santos P, Suarez A, Calatayud MT, Perez-Pinera P, Martinez M, Ribacoba R, Gutierrez C: Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer’s disease. J Alzheimers Dis 2008, 14:59-67.
• [21]Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR: Human kallikrein 6 as a biomarker of alzheimer’s disease. Clin Biochem 2000, 33:663-667.
• [22]Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP: Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008, 389:739-745.
• [23]Scarisbrick IA, Yoon H, Panos M, Larson N, Blaber SI, Blaber M, Rodriguez M: Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol 2012, 22:709-722.
• [24]Bando Y, Ito S, Nagai Y, Terayama R, Kishibe M, Jiang YP, Mitrovic B, Takahashi T, Yoshida S: Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci Lett 2006, 405:175-180.
• [25]Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA: Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J 2004, 18:920-922.
• [26]Martínez-Morillo E, Diamandis A, Romaschin AD, Diamandis EP: Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage. PLoS One 2012, 7:e45676.
• [27]Blaber M, Yoon H, Juliano MA, Scarisbrick IA, Blaber SI: Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis. Biol Chem 2010, 391:311-320.
• [28]Klimentzou P, Paravatou-Petsotas M, Zikos C, Beck A, Skopeliti M, Czarnecki J, Tsitsilonis O: Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha. Peptides 2006, 27:183-193.
• [29]Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT: Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 2009, 29:3269-3279.
• [30]Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G: Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000, 33:369-375.
• [31]Pavlopoulou A, Pampalakis G, Michalopoulos I, Sotiropoulou G: Evolution history of tissue kallikreins. PLoS One 2010, 5:e13781.
• [32]Wolf WC, Evans DM, Chao L, Chao J: A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol 2001, 159:1797-1805.
• [33]Kovacs-Nolan J, Mine Y: Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol 2012, 3:163-182.
• [34]Finlay JA, Day JR, Rittenhouse HG: Polyclonal and monoclonal antibodies to prostate-specific antigen can crossreact with human kallikrein 2 and human kallikrein 1. Urology 1999, 53:746-751.
• [35]Schade R, Calzado EG, Sarmiento R, Chacana PA, Porankiewicz-Asplund J, Terzolo HR: Chicken egg yold antibodies (IgY-technology). A review of progress in production and use in research and human and veterinary medicine. Altern Lab Anim 2005, 33:129-154.
• [36]Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP: Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005, 280:14628-14635.
• [37]Bayés A, Tsetsenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G: Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem 2004, 385:517-524.
• [38]Akita EM, Nakai S: Immunoglobulins form egg yolk: isolation and purification. J Food Sci 1992, 57:629-634.